To achieve closed-loop services for chronically ill patients.
I learned that the company in the field of chronic disease diagnosis and treatment Suo Mao Technology (original Asthma steward) has completed tens of millions of yuan in strategic financing, this round of financing is funded by medical and consumer industry packaging solution providers Aptar Aptar > Investment. Previously, Shuo Mao Technology had obtained two rounds of investment from Lanchi Ventures, Anlong Fund and other institutions.
It is reported that this round of financing will be used to promote and commercialize the core product, the disease diagnosis and treatment management system, and establish deeper cooperation with the hospital and explore business models , And talent team building.
About Shumo Technology, has had a detailed report on it , the initial positioning of the company was mainly aimed at R & D of intelligent monitoring equipment developers and remote pathology consulting services The main purpose of the provider is to monitor and evaluate the changes in the patient’s condition through intelligent devices and algorithms, and give medication reminders to help patients self-manage, so as to save them the time and energy spent on going to the hospital.
Now, the company has completed the extension and penetration from the patient side to the hospital side. Specifically, On the one hand, it will build an auxiliary analysis model for common respiratory diseases with the big data of lung function as the core of the hospital, helping the hospital and doctors Diagnosis and treatment of respiratory diseases; on the other hand, for patients with chronic respiratory diseases, use intelligent hardware to collect out-of-hospital pathological information, and finally combine these personalized information and the diagnosis of professional doctors to give corresponding interventions. Closed-loop services for sick patients.
Image source: Ruijing Creative
Specifically, Shuo Mao Technology will use big data and artificial intelligence technology to collect patient out-of-hospital pathological data through medical-grade sensors; at the same time, use disease outbreak models and data analysis The technology evaluates the patient’s condition in real time, and adjusts the intervention patient’s treatment plan in a timely manner; on the other hand, it can also help doctors and medical institutions to improve the daily clinical data dimension, improve clinical efficiency, and expand scientific research paths.
Luo Liang, CEO of Shuo Mao Technology, introduced that with the increasingly clear prospects of Internet medical care and the successive implementation of related supporting policies, the construction of Internet medical care has become the consensus of many hospitals, and hospitals have begun to actively embrace the Internet, which also gave Shuo Mao Technology provides opportunities to connect the hospital and the patients, and provides a systematic service for both ends.
According to Lu Liang ’s words, “Our biggest change is the previous positioning as a chronic disease service provider; today ’s positioning is to become a chronic disease management system and product provider, that is, to provide all parties in the medical industry chain Services, not only products for patients, but also products for hospitals, to better support the Internet-based construction of hospitals. “
Lv Liang said that as more and more hospitals obtain Internet hospital licenses and begin to establish an internal Internet hospital system, Shuo Mao Technology is in the respiratory department ) And the accumulation in the field of pediatrics (asthma), fully capable of helping the hospital to complete the construction of the above-mentioned sectors, that is, the existing management system and model are grafted into the existing hospital system, and the mobile application and WeChat applet can be used to open the patient’s hospital Data to provide a convenient platform for remote follow-up and disease management of chronically ill patients.
It is reported that currently Suomao Technology has reached this agreement with the three top three hospitals in Shanghai Cooperation intention.
In terms of software and hardware products, Shuo Mao Technology also has many products landing. In addition to the lung function instrument and auxiliary analysis system for hospitals, there are also a series of equipment for patients, such as electronic peak velocity meter, intelligent inhaler, high-end Nasal aspirator, etc.
As of now, Suo Mao Technology has owned China CFDA, EU CE, US FDA , Japan ’s Ministry of Health, Welfare, and other regulatory authorities issued certifications , its products have covered nearly 1,000 hospitals at all levels; in addition, in 2019, the company ’s products help primary hospitals Over 100,000 patients with chronic diseases of the respiratory system were examined. Based on this, the company has also achieved very stable cash flow, close to breakeven.
Speaking of Aptar’s capital injection, Lu Liang said that Aptar has a mature position in the entire value chain of global drug delivery technology. In the future, Aptar will cooperate with Shumao Technology in the field of digital disease management platforms and algorithms, and develop, produce, and commercialize new-generation digital intelligent drug delivery devices. Cooperation.
It is reported that the collaboration will be the first to focus on integrating digital devices and platforms for asthma and chronic obstructive pulmonary disease (COPD), and jointly expand Shuo Mao ’s platform services , In order to achieve remote patient medication monitoring; in addition, the two parties will cooperate with pharmaceutical and healthcare companies to accelerate the development, manufacturing, commercialization and supply of respiratory medicines that have been marketed and under development, to achieve drug delivery, diagnosis and patient support Digitization.